$0.18 0.0 0.0%
Last Trade - 23/02/21
| Market Cap | ÂŁ12.6m |
| Enterprise Value | ÂŁ13.7m |
| Revenue | ÂŁn/a |
| Position in Universe | 6061st / 6715 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.28 | 0.26 | 0.25 | 0.19 | 0.000 | 0.000 | -100.0% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Bioxytran, Inc., formerly U.S. Rare Earth Minerals, Inc., is a developmental stage biotechnology company. The Company is focused on developing anti-necrosis drugs that treat an inadequate blood supply to an organ by delivering oxygen. Its oxygen delivery platform is being developed to treat victims with brain stroke trauma. Its pipeline includes BXT-25 and BXT-252. BXT-25 is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked and it is based on molecule reversing hypoxia (oxygen deficiency). BXT-252 is a resuscitative agent in a variety of wound healing applications. BXT-252 is designed to treat chronic wounds resulting from ischemia caused by occlusion of capillaries.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | June 9, 2008 |
| Public Since | March 22, 2007 |
| No. of Shareholders: | 1,005 |
| No. of Employees: | 2 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Pink Sheets on Nasdaq |
| Shares in Issue | 97,187,673 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 233 Needham St Ste 300, NEWTON UPPER FALLS, 02464-1502, United States |
| Web | https://www.bioxytraninc.com/ |
| Phone | +1 617 4941199 |
| Contact | () |
| Auditors | Pinnacle Accountancy Group of Utah |
As of 23/02/21, shares in Bioxytran Inc are trading at $0.18, giving the company a market capitalisation of ÂŁ12.6m. This share price information is delayed by 15 minutes.
Shares in Bioxytran Inc are currently trading at $0.18 and the price has moved by -40% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bioxytran Inc price has moved by -54.21% over the past year.
There are no analysts currently covering Bioxytran Inc.
Bioxytran Inc is scheduled to issue upcoming financial results on the following dates:
Bioxytran Inc does not currently pay a dividend.
Bioxytran Inc does not currently pay a dividend.
Bioxytran Inc does not currently pay a dividend.
To buy shares in Bioxytran Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Bioxytran Inc are currently trading at $0.18, giving the company a market capitalisation of ÂŁ12.6m.
Here are the trading details for Bioxytran Inc:
Based on an overall assessment of its quality, value and momentum, Bioxytran Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Bioxytran Inc are currently priced at $0.18. At that level they are trading at 1.37% discount to the analyst consensus target price of 0.00.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioxytran Inc. Over the past six months, the relative strength of its shares against the market has been 0.608k%. At the current price of $0.18, shares in Bioxytran Inc are trading at -25.26% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Bioxytran Inc.
Bioxytran Inc's management team is headed by:
Here are the top five shareholders of Bioxytran Inc based on the size of their shareholding:
